Prof. Kenneth To is currently an Associate Professor in the Chinese University of Hong Kong. He received post-doctoral training at the National Cancer Institute, National Institute of Health, USA, investigating the mechanisms of multidrug resistance and cancer epigenetics. After he became an independent investigator, his research interests focus on the development of novel strategies to overcome drug resistance to classical cytotoxic anticancer drugs as well as molecular targeted cancer therapeutics. He has served as Guest Associate Editor (Frontiers in Oncology & Frontiers in Genetics), Consulting Editor (Pharmacology Research and Perspectives) and Editorial Board Member in 4 other journals in the fields of cancer research and pharmacology. He published more than 100 peer-reviewed articles in highly ranked scientific journals in cancer biology and pharmacology.